JPMorgan Chase & Co. Cuts Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $40.00

Posted by Brian Himes on Aug 11th, 2026

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) had its target price dropped by equities researchers at JPMorgan Chase & Co. from $44.00 to $40.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 98.12% from the stock’s previous close.

SNDX has been the topic of a number of other reports. Bank of America reaffirmed a “buy” rating on shares of Syndax Pharmaceuticals in a research note on Wednesday, August 5th. UBS Group restated a “buy” rating on shares of Syndax Pharmaceuticals in a report on Friday, June 12th. Weiss Ratings lowered Syndax Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. Barclays lifted their target price on shares of Syndax Pharmaceuticals from $35.00 to $37.00 and gave the stock an “overweight” rating in a research note on Friday, May 1st. Finally, HC Wainwright reduced their target price on shares of Syndax Pharmaceuticals from $40.00 to $38.00 and set a “buy” rating for the company in a research report on Wednesday, August 5th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $41.91.

Check Out Our Latest Report on Syndax Pharmaceuticals

Syndax Pharmaceuticals Price Performance

Syndax Pharmaceuticals stock traded down $0.18 during midday trading on Tuesday, reaching $20.19. The company had a trading volume of 232,640 shares, compared to its average volume of 1,613,328. The company has a market capitalization of $1.79 billion, a P/E ratio of -8.04 and a beta of 0.40. Syndax Pharmaceuticals has a 12-month low of $12.62 and a 12-month high of $25.59. The firm’s fifty day simple moving average is $20.46 and its 200-day simple moving average is $21.37. The company has a debt-to-equity ratio of 38.95, a current ratio of 6.77 and a quick ratio of 6.44.

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.10). Syndax Pharmaceuticals had a negative return on equity of 372.94% and a negative net margin of 87.52%.The firm had revenue of $72.79 million for the quarter, compared to analysts’ expectations of $79.36 million. During the same quarter last year, the firm posted ($0.83) earnings per share. Syndax Pharmaceuticals’s quarterly revenue was up 91.8% on a year-over-year basis. As a group, equities analysts anticipate that Syndax Pharmaceuticals will post -1.87 EPS for the current year.

Insider Buying and Selling at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, CMO Nicholas A.J. Botwood sold 31,235 shares of the firm’s stock in a transaction on Friday, June 12th. The stock was sold at an average price of $18.14, for a total value of $566,602.90. Following the completion of the sale, the chief marketing officer directly owned 60,885 shares of the company’s stock, valued at $1,104,453.90. This trade represents a 33.91% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael A. Metzger sold 32,375 shares of Syndax Pharmaceuticals stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $24.24, for a total value of $784,770.00. Following the transaction, the chief executive officer owned 484,843 shares in the company, valued at approximately $11,752,594.32. This represents a 6.26% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 105,914 shares of company stock valued at $2,120,789. 4.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. E Fund Management Co. Ltd. acquired a new position in Syndax Pharmaceuticals in the 2nd quarter valued at about $301,000. BlackRock Inc. acquired a new stake in shares of Syndax Pharmaceuticals during the 2nd quarter worth approximately $197,177,000. Pallas Capital Advisors LLC acquired a new stake in shares of Syndax Pharmaceuticals during the 2nd quarter worth approximately $207,000. Deutsche Bank AG acquired a new stake in shares of Syndax Pharmaceuticals during the 2nd quarter worth approximately $2,084,000. Finally, Bank of New York Mellon Corp acquired a new position in Syndax Pharmaceuticals in the second quarter valued at approximately $22,736,000.

About Syndax Pharmaceuticals

(Get Free Report)

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.